A PROSPECTIVE, RANDOMIZED STUDY OF COADMINISTRATION OF KETOCONAZOLE AND CYCLOSPORINE A IN KIDNEY TRANSPLANT RECIPIENTS: TEN-YEAR FOLLOW-UP

Abstract

We conclude that the long-term use of keto for CsA dose reduction in kidney transplant recipients is safe, tolerable, and cost-sparing and is associated with stable graft function.